|
Heart failure
|
0.010 |
Biomarker
|
disease |
BEFREE |
Here, we investigated the role of A1R signaling at physiologically relevant ADO concentrations on HF SAN pacemaker cells.
|
31751583 |
2020 |
|
Congestive heart failure
|
0.010 |
Biomarker
|
disease |
BEFREE |
Here, we investigated the role of A1R signaling at physiologically relevant ADO concentrations on HF SAN pacemaker cells.
|
31751583 |
2020 |
|
Uveitis
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Genome-wide association study (GWAS) provided a powerful tool for genome-wide level analysis to explore the genetic predisposition for uveitis and revealed several genes to be associated with uveitis including IL23R/C1orf141, STAT4 and ADO/ZNF365/EGR2.
|
31669406 |
2020 |
|
Malignant tumor of cervix
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
The present study analyzed the participation of Ado, generated through the functional activity of the cervical cancer (CeCa) pathway in CeCa cells, to induce the expression and secretion of TGF-β1, as well as the participation of this factor to maintain CD73 expression.
|
30301599 |
2019 |
|
Seizures
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
All A1AR agonists were efficacious in preventing seizure and promoting survival.
|
31069755 |
2019 |
|
Malnutrition
|
0.010 |
Biomarker
|
disease |
BEFREE |
ADO and RFA could be excellent sources of protein and bioavailable Fe, making it a sustainable, low-cost food source to prevent malnutrition in humans.
|
31623146 |
2019 |
|
Cervix carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
The present study analyzed the participation of Ado, generated through the functional activity of the cervical cancer (CeCa) pathway in CeCa cells, to induce the expression and secretion of TGF-β1, as well as the participation of this factor to maintain CD73 expression.
|
30301599 |
2019 |
|
cervical cancer
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
The present study analyzed the participation of Ado, generated through the functional activity of the cervical cancer (CeCa) pathway in CeCa cells, to induce the expression and secretion of TGF-β1, as well as the participation of this factor to maintain CD73 expression.
|
30301599 |
2019 |
|
Behcet Syndrome
|
0.010 |
Biomarker
|
disease |
BEFREE |
Our findings confirmed the association of four loci (<i>LACC1</i>, <i>CEBPB-PTPN1</i>, <i>ADO-EGR2</i> and <i>RIPK2</i>) in Chinese Han patients with BD.
|
29907633 |
2018 |
|
Malignant Neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
In this study, we have predicted a 3D model structure for ADO and summarized the biological roles and the pathological consequences which are associated with the altered expression and functioning of ADO and CDO in case of cancer, neurodegenerative disorders and other human diseases.
|
28439920 |
2017 |
|
Fenestration (morphologic abnormality)
|
0.010 |
Biomarker
|
disease |
BEFREE |
Patients in whom fenestration closure was performed with an ADO II and who had at least 6 months of follow-up were included in this study.
|
28261286 |
2017 |
|
Atrial Septal Defects
|
0.010 |
Biomarker
|
group |
BEFREE |
Among the 114 patients submitted to ADO II-AS implantation at our institution, 12 received this device as off-label treatment of paravalvular leak (n = 5), sinus of Valsalva fissuration (n = 2), accessory atrial septal defect (n = 2), muscular ventricular septal defect (n = 1), bleeding bronchial artery aneurysm (n = 1) and reverse shunt due to abnormal origin of left subclavian artery from pulmonary artery (n = 1).
|
27898501 |
2017 |
|
Ventricular Septal Defects
|
0.010 |
Biomarker
|
group |
BEFREE |
The CHB that is a major challenge for closure of VSDs is less common with soft, specially designed ADO II, which does not compress the conducting system.
|
24130123 |
2017 |
|
Complete atrioventricular block
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Use of the ADO II in non-ductal positions can be achieved with high success and low complication rates, especially CHB; its use is also associated with significantly reduced procedure time and device cost.
|
24130123 |
2017 |
|
Aorta to right ventricle tunnel
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Out of 79 defects closed with ADO II, 61 had perimembranous, 12 apical/mid-muscular ventricular septal defects (VSD), 4 Gerbode defects, one each of coronary arterio-venous fistula and aorto-right ventricular tunnel.
|
24130123 |
2017 |
|
Neurodegenerative Disorders
|
0.010 |
Biomarker
|
group |
BEFREE |
In this study, we have predicted a 3D model structure for ADO and summarized the biological roles and the pathological consequences which are associated with the altered expression and functioning of ADO and CDO in case of cancer, neurodegenerative disorders and other human diseases.
|
28439920 |
2017 |
|
Primary malignant neoplasm
|
0.010 |
Biomarker
|
group |
BEFREE |
In this study, we have predicted a 3D model structure for ADO and summarized the biological roles and the pathological consequences which are associated with the altered expression and functioning of ADO and CDO in case of cancer, neurodegenerative disorders and other human diseases.
|
28439920 |
2017 |
|
Pulmonary arterial hypertension
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
We report interventional re-opening of a PDA for reverse Potts shunt circulation 12 months after closure in a 3.8 year old child, suffering from right ventricular (RV) failure due to suprasystemic pulmonary artery hypertension (PAH) after ADO I implantation.
|
27516058 |
2017 |
|
Idiopathic pulmonary arterial hypertension
|
0.010 |
Biomarker
|
disease |
BEFREE |
We report interventional re-opening of a PDA for reverse Potts shunt circulation 12 months after closure in a 3.8 year old child, suffering from right ventricular (RV) failure due to suprasystemic pulmonary artery hypertension (PAH) after ADO I implantation.
|
27516058 |
2017 |
|
Bronchial artery aneurysm
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Among the 114 patients submitted to ADO II-AS implantation at our institution, 12 received this device as off-label treatment of paravalvular leak (n = 5), sinus of Valsalva fissuration (n = 2), accessory atrial septal defect (n = 2), muscular ventricular septal defect (n = 1), bleeding bronchial artery aneurysm (n = 1) and reverse shunt due to abnormal origin of left subclavian artery from pulmonary artery (n = 1).
|
27898501 |
2017 |
|
Osteosclerosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Autosomal dominant osteopetrosis type II (ADO-II) is a heritable bone disorder characterized by osteosclerosis, predominantly involving the spine (vertebral end-plate thickening, or rugger-jersey spine), the pelvis ("bone-within-bone" structures) and the skull base.
|
26056022 |
2016 |
|
Tumor Progression
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Emerging evidence suggests that the adenosine (Ado) receptors may play crucial roles in tumor progression.
|
27911956 |
2016 |
|
Oestrogen receptor positive breast cancer
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
There was weaker evidence for iCHAV4, located 5' of ADO, associated only with ER-positive breast cancer (OR = 0.93 [0.90-0.96]).
|
26073781 |
2015 |
|
Colitis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Given the central role of intestinal epithelial cells to the development of colitis, we hypothesized that specific Ado receptors would contribute to disease resolution in mucosal inflammation as modeled by dextran sodium sulfate (DSS) colitis.
|
19342675 |
2009 |
|
Carney Complex
|
0.010 |
Biomarker
|
disease |
BEFREE |
The objective of the study was to study the antiproliferative effects of 8-Cl-ADO on growth and proliferation in B-lymphocytes of Carney complex patients that have PKA defects and to determine whether 8-CL-ADO could be used as a therapeutic agent in the treatment of Carney complex-associated tumors.
|
19773399 |
2009 |